1. Market Research
  2. > Pharmaceutical
  3. > OTC Market Trends
Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030

Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030

  • January 2021
  • 190 pages
  • ID: 5993608
  • Format: PDF
  • Delve Insight

Summary

Table of Contents

‘Smoking Cessation—Market Insights, Epidemiology, and Market Forecast–2030’ report deliver an in-depth understanding of the Smoking Cessation, historical and forecasted epidemiology as well as the Smoking Cessation market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
The Smoking Cessation market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Smoking Cessation market size from 2017 to 2030. The Report also covers current Smoking Cessation treatment practice/algorithm, market drivers, market barriers, unmet medical needs, SWOT analysis to curate the best of the opportunities, and assesses the underlying potential of the market.

Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2017–2030
Smoking Cessation Understanding and Treatment Algorithm

Smoking Cessation Overview
Smoking cessation is the process of discontinuing tobacco smoking. When a person smokes tobacco in cigarettes, cigars or pipes, they absorb toxins that can lead to various health problems such as diabetes, cancer, chronic obstructive pulmonary disease (COPD), heart diseases, lung diseases, etc.
The main barrier to smoking cessation is nicotine addiction. Some of the most common nicotine withdrawal symptoms smokers face when they try to quit smoking include craving for smoking, mood swings, insomnia, constipation, increased appetite, anxiety, etc.

Smoking Cessation Symptoms
Stopping smoking brings about a variety of symptoms associated with physical and psychological withdrawal. Most symptoms decrease sharply during the first few days of quitting, followed by a continued, but slower rate of decline in the second and third week of abstinence. For some people, coping with withdrawal symptoms is like “riding a roller coaster”—there may be sharp turns, slow climbs, and unexpected plunges. Most symptoms pass within 2–4 weeks after stopping.
Continued in the report…..

Smoking Cessation Treatment
The treatment of smoking includes various options such as nicotine replacement therapy (NRT), non-nicotinic pharmacological therapies, behavioral therapies, and counseling.
Varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Nortriptyline and clonidine are also used in smoking cessation as off-label medicines.
In the United States, NRT is available over the counter or by prescription as patches, gum, and lozenges, and by prescription only as a nasal spray and oral inhaler. NRT provides nicotine to reduce withdrawal symptoms, including irritability, anxiety, difficulty concentrating, dysphoria, hunger, weight gain, and sleep disturbances, which occur when a smoker stops smoking.
Non-pharmacological treatments for tobacco dependence include behavioral skills training using cognitive behavioral therapy techniques, motivational interviewing, and incentives to motivate and reinforce behavior change.

Smoking Cessation Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Prevalent Cases of Smokers, Gender-specific Diagnosed Prevalent Cases of Smokers, Age-specific Diagnosed Prevalent Cases of Smokers and Total Diagnosed Prevalent Cases of Smoking Cessation in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Key Findings
• The total diagnosed prevalent population of Smoking Cessation in the 7MM was 49,301,950 in 2017.
• The United States showed the highest diagnosed prevalent cases of smokers, as compared to EU5, and Japan. In 2017, the number of smokers in the US was estimated to be 35,288,932.
• In the US, there were 19,303,046 diagnosed prevalent cases of smokers among males and 15,985,886 diagnosed prevalent cases among females in 2017.
• Out of the total 35,288,932 diagnosed prevalent cases of smokers in the US, the highest cases were observed in the age group 45–64 years (14,080,284) and the least cases were observed in 18-24 years (3,140,715) in the year 2017.
• Among the European-5 countries, Germany had the highest diagnosed prevalent population of smokers with 19,305,099 cases, followed by France with 14,044,812 cases. On the other hand, the United Kingdom had the lowest diagnosed prevalent population of 7,750,777 in 2017.
• Japan had 19,411,835 diagnosed prevalent cases of smokers in 2017, and out of this approximately 5,610,020 diagnosed cases of smoking cessation were estimated.

Smoking Cessation Epidemiology
The epidemiology segment also provides the Smoking Cessation epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Smoking Cessation Drug Chapters
The drug chapter segment of the Smoking Cessation report encloses the detailed analysis of Smoking Cessation current therapies, mid-phase, and late-stage pipeline drugs. It also helps to understand the Smoking Cessation clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details of each included drug, and the latest news and press releases.

Smoking Cessation Marketed Drugs
Varenicline (Chantix/Champix): Pfizer
Varenicline is a medication used for smoking cessation aids. It works by blocking the pleasant effects of nicotine (from smoking) on the brain. It is used together with behavior modification and counseling support to help stop smoking. In May 2006, the US FDA approved varenicline (Chantix, Champix) for use in smoking cessation; it was the first oral non?nicotine treatment licensed by the FDA. It was also approved in the EU and Japan for smoking cessation. Patients should be treated with Chantix for 12 weeks. For patients who have successfully stopped smoking at the end of 12 weeks, an additional course of 12 weeks of treatment with Chantix is recommended to increase the likelihood of long-term abstinence further.
Varenicline binds with high affinity and selectivity at ?4?2 neuronal nicotinic acetylcholine receptors. The efficacy of Chantix in smoking cessation is believed to be the result of varenicline’s activity at the ?4?2 sub-type of the nicotinic receptor where its binding produces agonist activity, while simultaneously preventing nicotine binding to these receptors.
Products detail in the report…
Bupropion (Zyban): GlaxoSmithKline
Bupropion is a selective inhibitor of the neuronal reuptake of catecholamines (noradrenaline and dopamine) with minimal effect on the re-uptake of indolamines (serotonin). It is indicated as an aid to smoking cessation treatment. The exact mechanism by which Zyban enhances the ability of patients to abstain from smoking is not known but is presumed to be related to noradrenergic and/or dopaminergic mechanisms. Bupropion is a relatively weak inhibitor of the neuronal reuptake of norepinephrine and dopamine and does not inhibit the reuptake of serotonin. Bupropion does not inhibit monoamine oxidase. The FDA approved it in 1997. It is also approved in the EU for the treatment of smoking cessation.
Products detail in the report…

Smoking Cessation Emerging Drugs
AXS-05: Axsome Therapeutics
AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity, in clinical development for major depressive disorder (MDD), Alzheimer’s disease (AD) agitation, and smoking cessation. The drug consists of dextromethorphan (DM) and bupropion and utilizes Axsome’s metabolic inhibition technology. The DM component of AXS-05 is a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, sigma-1 receptor agonist, and an inhibitor of the serotonin and norepinephrine transporters. The bupropion component of AXS-05 serves to increase the bioavailability of DM and is a norepinephrine and dopamine reuptake inhibitor. Both components are nicotinic acetylcholine receptor antagonists and have demonstrated anti-inflammatory properties. The company plans to meet with the FDA in the second half of 2020 to discuss the continued clinical development of AXS-05 as an aid to smoking cessation treatment.
Products detail in the report…
Nadolol (INV102): Chronic Airway Therapeutics
Nadolol (INV102) is a beta-adrenergic biased ligand targeted to reverse mucous metaplasia in the airway epithelium to treat chronic respiratory diseases. Used acutely, Nadolol blocks both ?1 and ?2 receptors, causing a decrease in heart rate and blood pressure via ?1 receptors, which are located predominantly in the heart, and causing airway constriction via ?2 receptors, located predominantly in the bronchial muscle of the airways. The drug is currently marketed under various brands including Corgard and Novo-Nadolol. The company evaluated nadolol in a phase II clinical trial, and results show that it is safe and effective in smoking cessation.
Products detail in the report…
Cytisinicline (cytisine): Achieve Life Sciences
Cytisinicline (also known as cytisine) is an oral, plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe (as Tabex) for more than 20 years. Cytisinicline’s dual-acting MOA specifically targets the ?4?2 nicotine receptor. Through its partial agonist/partial antagonist activity, it is believed to help reduce nicotine cravings, withdrawal symptoms, and reward and satisfaction associated with smoking. The company is launching a phase III clinical trial in Q4 with designs and NDA plans already reviewed with the FDA. It was also studied in phase III clinical trial comparing cytosine and varenicline. Achieve Life Sciences also completed the development of phase II ORCA-V1 trial protocol to evaluate cytisinicline in this rapidly growing population of e-cigarette users. Currently, the company is pursuing non-dilutive funding sources to help support this initiative.
Products detail in the report…
List to be continued in the report…

Smoking Cessation Market Outlook
There are effective treatments that support tobacco cessation, including both behavioral therapies and FDA-approved medications. There are 89 distinct products and services available today for smoking cessation, alongside 12 smoking alternatives that are not specifically indicated for cessation. FDA-approved pharmacotherapies include various forms of nicotine replacement therapy (NRT) in the form of a transdermal patch, gum, nasal spray, oral inhaler, and lozenges; bupropion; and, most recently, varenicline. Nortriptyline and clonidine have been shown in clinical trials to promote smoking cessation, but regulatory authorities have not approved them for this purpose.
In the EU, varenicline (Champix) and bupropion-SR (Zyban) are approved for smoking cessation. Cytisine is a generic agent currently manufactured by Sopharma as Tabex and by Aflofarm Pharma as Desmoxan. It has been available both with and without prescription for smoking cessation since the 1960s, largely in Eastern Europe. The basic patent of Chantix/Champix is about to expire in 2021 in the EU and in 2022 in Japan. In Japan, varenicline (Champix), NRT, and some off-label therapies are used for smoking cessation. Bupropion-SR is not licensed in Japan for smoking cessation.
For smokeless tobacco users, counseling and support in changing behavior appear to be effective, while the evidence for nicotine replacement and other drugs is weak. Nonpharmacologic therapy, such as individual or group counseling, is necessary to address the important role of conditioning in tobacco addiction, which is not completely addressed using pharmacologic means. Briefly, ideal characteristics of effective nonpharmacologic treatment include those that improve skills necessary to achieve and maintain abstinence, such as those that teach coping mechanisms for craving and aversive abstinence symptoms.
According to the report, Smoking Cessation 7MM is expected to change in the study period 2017–2030.

Key Findings
• The market size of Smoking Cessation in the 7MM was USD 2,874.8 million in 2017.
• According to the estimates, the highest market size of smoking cessation is found in the United States, followed by Japan and France.
• The current market for Smoking Cessation includes three major therapies Varenicline (Chantix), Bupropion-SR (Zyban), and nicotine replacement therapies (NRT). NRT includes inhaler, nasal spray, patch, gum, and lozenge.
• The emerging therapies for Smoking Cessation include AXS-05, Cytisinicline, and NFL-101, which are expected to enter the market during the forecasted period (2020–2030).
• Among the EU-5 countries, France has the highest market size of USD 151.3 million, followed by Spain and the United Kingdom in 2017. The lowest market size was estimated in Germany with USD 77.8 million in 2017.
• The total market size of Smoking Cessation in Japan was estimated to be USD 333.5 million in 2017.

The United States Market Outlook
This section provides the total Smoking Cessation market size and; market size by therapies in the United States.

EU-5 Market Outlook
The total Smoking Cessation market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook
The total Smoking Cessation market size and market size by therapies in Japan are provided.
Smoking Cessation Drugs Uptake
This section focuses on the rate of uptake of the drugs expected to get launched in the market during the study period 2017–2030. The analysis covers Smoking Cessation market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Smoking Cessation Development Activities
The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Smoking Cessation emerging therapies.
Reimbursement Scenario in Smoking Cessation
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
Competitive Intelligence Analysis
We perform competitive and market Intelligence analysis of the Smoking Cessation market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report
• The report covers the descriptive overview of Smoking Cessation, explaining symptoms of nicotine withdrawal and currently available therapies.
• Comprehensive insight has been provided into the Smoking Cessation epidemiology and treatment.
• Additionally, an all-inclusive account of both the current and emerging therapies for Smoking Cessation is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
• A detailed review of the Smoking Cessation market; historical and forecasted is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Smoking Cessation market.

Report Highlights
• The increasing diagnosed prevalence of the Smoking Cessation along with promising emerging pipeline therapies will positively drive the Smoking Cessation market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Smoking Cessation R&D.
• Major players are involved in developing therapies for Smoking Cessation. The launch of emerging therapies will significantly impact the Smoking Cessation market.
• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Smoking Cessation Report Insights
• Patient Population
• Therapeutic Approaches
• Smoking Cessation Pipeline Analysis
• Smoking Cessation Market Size and Trends
• Market Opportunities
• Impact of Upcoming Therapies

Smoking Cessation Report Key Strengths
• Eleven Years Forecast
• 7MM Coverage
• Smoking Cessation Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Smoking Cessation Report Assessment
• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers
• SWOT Analysis
• Market Access and Reimbursement

Key Questions

Market Insights:
• What was the Smoking Cessation market share (%) distribution in 2017 and how it would look like in 2030?
• What would be the Smoking Cessation total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?
• What are the key findings pertaining to the market across the 7MM and which country will have the largest Smoking Cessation market size during the forecast period (2020–2030)?
• At what CAGR, the Smoking Cessation market is expected to grow at the 7MM level during the forecast period (2020–2030)?
• What would be the Smoking Cessation market outlook across the 7MM during the forecast period (2020–2030)?
• What would be the Smoking Cessation market growth till 2030 and what will be the resultant market size in the year 2030?
• How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:
• What are the disease risk, burden, and unmet needs of Smoking Cessation?
• What is the historical Smoking Cessation patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
• What would be the forecasted patient pool of Smoking Cessation at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Smoking Cessation?
• Out of the above-mentioned countries, which country would have the highest diagnosed prevalent population of Smoking Cessation during the forecast period (2020–2030)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
• What are the current options for the treatment of Smoking Cessation along with the approved therapy?
• What are the Smoking Cessation emerging drugs and their MOA, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
• How many companies are developing therapies for Smoking Cessation?
• How many emerging therapies are in the mid-stage and late stages of development for Smoking Cessation?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Smoking Cessation therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Smoking Cessation and their status?
• What are the key designations that have been granted for the emerging therapies for Smoking Cessation?
• What are the 7MM historical and forecasted market of Smoking Cessation?

Reasons to buy
• The report will help in developing business strategies by understanding trends shaping and driving the Smoking Cessation.
• To understand the future market competition in the Smoking Cessation market and Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Smoking Cessation in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for the Smoking Cessation market.
• To understand the future market competition in the Smoking Cessation market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Smoking Cessation-Epidemiology Forecast–2030

  • $ 3750
  • January 2021
  • 80 pages

‘Smoking Cessation-Epidemiology Forecast–2030’ report delivers an in-depth understanding of the smoking cessation, historical and forecasted epidemiology as well as the smoking cessation trends in ...

  • United States
  • Japan
  • Smoking Cessation
  • Industry analysis

ref:plp2020

Reportlinker.com © Copyright 2021. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on